Fig. 1 (g) and (h) presents an assessment of the proportion of CD19+/IgD−/CD27++ plasmablasts before vaccination (upper left quadrant) and after vaccination (upper right quadrant) and an assessment of the proportion of CD19+/IgM/CD38++ plasmablasts before vaccination (lower left quadrant) and 7 days after vaccination (lower right quadrant) in a CLL patient who did not respond to PCV13 vaccine administration (g) and in a healthy subject from the control group, who responded to PCV13 vaccine administration (h). This evidence concerns the gene CD38 and B-cell chronic lymphocytic leukemia.